ArticlePloS one2026
GBP2 promotes podocyte pyroptosis and contributes to the pathogenesis of pediatric lupus nephritis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLupus nephritis (LN), a prevalent and serious manifestation of systemic lupus erythematosus, exhibits particularly high incidence in children, yet its pathogenesis remains incompletely elucidated. This study aimed to investigate differentially expressed genes in LN and elucidate their regulatory mechanisms.
methodsBioinformatics analysis was conducted on the publicly available glomerular gene expression dataset GSE32591 from the Gene Expression Omnibus to identify hub genes. Based on this screening, Guanylate-binding protein 2 (GBP2) was selected for further investigation. In vivo, GBP2 expression was assessed in renal tissues from pediatric LN patients by immunohistochemistry. In a murine LN model, the expression levels of GBP2 and key pyroptosis-associated markers were evaluated using immunohistochemistry, RT-qPCR, and western blotting. In vitro, a podocyte pyroptosis model was induced by lipopolysaccharide and adenosine triphosphate treatment. Functional experiments involving Gbp2 knockdown and overexpression, followed by a rescue experiment where absent in melanoma 2 (Aim2) was overexpressed in Gbp2-knockdown cells, were performed to elucidate its role and underlying mechanisms in regulating pyroptosis.
resultsBioinformatics analysis identified OAS1, OAS2, IRF7, GBP2, and GBP1 as hub genes. An upregulation of GBP2 and gasdermin D (GSDMD) was observed in the glomeruli of children with LN, showing a strong correlation with 24-hour urinary protein excretion. Renal tissues from LN mice exhibited markedly increased expression of GBP2, AIM2, Caspase-1, and GSDMD compared to controls. Following siRNA-mediated knockdown of Gbp2 in vitro, a consequent reduction was observed in pyroptosis-associated proteins (GSDMD, AIM2) and diminished secretion of the pro-inflammatory cytokines IL-1β and IL-18. Conversely, Gbp2 overexpression aggravated these effects. Pyroptosis suppressed by Gbp2 knockdown was partially restored upon concurrent overexpression of Aim2.
conclusionOur results demonstrate that GBP2 expression is significantly upregulated in LN and promotes podocyte pyroptosis, likely contributing to renal injury. These findings suggest that GBP2 facilitates the progression of pediatric LN by activating the pyroptotic pathway and triggering the release of inflammatory cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.